Ryan Flinn

1 week ago | managedhealthcareexecutive.com | Ryan Flinn

A one-time gene editing treatment by Verve Therapeutics reduced low-density lipoprotein (LDL) cholesterol by nearly 70% in patients with inherited or premature cardiovascular disease, according to early clinical trial results released this week. In the phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 led to a mean LDL reduction of 53% among patients receiving the highest dose, with the maximum individual reduction reaching 69%, the company said in a news release.

1 week ago | managedhealthcareexecutive.com | Ryan Flinn

Researchers have uncovered a surprising mechanism linking Parkinson’s disease and melanoma, potentially explaining why people with one condition face higher risks of developing the other. The culprit: a protein called alpha-synuclein that plays dramatically different roles in neurons versus skin cancer cells.

2 weeks ago | managedhealthcareexecutive.com | Ryan Flinn

An experimental gene therapy from Lexeo Therapeutics may provide a new treatment option for Friedreich ataxia (FA) cardiomyopathy, a rare and often fatal heart complication tied to the neurodegenerative disorder. Interim results from two early-stage studies suggest the therapy not only boosts production of a crucial mitochondrial protein but also meaningfully improves heart function, the company said in a news release.

2 weeks ago | managedhealthcareexecutive.com | Ryan Flinn

Patients with mucous membrane pemphigoid (MMP) face nearly double the risk of developing certain skin cancers compared to the general population, according to a large-scale study published in Frontiers in Medicine.

3 weeks ago | managedhealthcareexecutive.com | Ryan Flinn

Rare disease gene therapies are more than twice as likely to earn FDA approval compared with other drug types, according to a new analysis. The study, published in Nature Reviews Drug Discovery, found that 19% of rare disease gene therapy programs that enter phase 1 eventually succeed — compared with just 7.3% of drug programs overall.